Copyright: ©Author(s) 2026.
World J Crit Care Med. Sep 9, 2026; 15(3): 122062
Published online Sep 9, 2026. doi: 10.5492/wjccm.122062
Published online Sep 9, 2026. doi: 10.5492/wjccm.122062
Table 2 Disease state under study and method of congestion measurement, n (%)
| Variable | Number of studies |
| Disease state | |
| Cardiac | 116 (80.0) |
| Heart failure | 107 |
| Right heart failure | 1 |
| ACS | 6 |
| Cardiac surgery | 2 |
| Pulmonary | 7 (4.8) |
| Dyspnea | 4 |
| Pulmonary hypertension | 3 |
| Gastrointestinal | 10 (6.9) |
| Cirrhosis | 3 |
| Cardiac congestive hepatopathy | 6 |
| Cardiac induced intra-abdominal hypertension | 1 |
| Renal | 8 (5.5) |
| Dialysis | 5 (3.4) |
| Cardiac congestive nephropathy | 3 (2.1) |
| Peripheral congestion | 4 (2.8) |
| Method of identifying congestion | |
| Physical exam | 65 (44.8) |
| Echocardiography | 56 (38.6) |
| Lung ultrasound | 24 (16.6) |
| Hepatic/abdominal ultrasound | 9 (6.2) |
| Renal ultrasound | 5 (3.4) |
| Clinical congestion score used | 40 (27.6) |
- Citation: Van Nynatten LR, Nabieva K, Barber G, Moroniti JJ, Iansavitchene A, Prager R, Slessarev M, Basmaji J, Leligdowicz A. Characterizing the molecular landscape of venous congestion. World J Crit Care Med 2026; 15(3): 122062
- URL: https://www.wjgnet.com/2220-3141/full/v15/i3/122062.htm
- DOI: https://dx.doi.org/10.5492/wjccm.122062